Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR16 phase II placebo-controlled study in Huntington disease
2004-000394-60Phase 2Completed
- Sponsor
- Carlsson Research
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing ACR16 with Placebo (2 arms). Primary endpoint: Change in weighted total cognitive score. Started May 2004; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2004-000394-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000394-60.